Stereotaxis, Inc. (NASDAQ:STXS) today announced the completion of the first 50 clinical procedures using the Company’s new Niobe ES system to treat patients with a variety of complex cardiac arrhythmias. A majority of the first 50 cases were performed to treat atrial fibrillation (AF), the most common type of cardiac arrhythmia. Positive initial results with the Niobe ES system in Europe demonstrate that the average time for completion of mapping and ablation for the initial AF patients was 69 minutes. The data will be featured at the Boston Atrial Fibrillation Symposium 2012 to be held on January 12-14, 2012 .
Professor Carlo Pappone of Villa Maria Cecilia Hospital , Cotignola Italy, commented:
“My vision was to click on the map and for the catheter to quickly and precisely move to that spot. Today with the Epoch platform, this is a reality. I believe the Epoch platform is one of the most important innovations for the EP practice to date. With the Epoch technology all physicians can successfully and consistently perform high quality AF procedures with the assurance of superior patient care.”
Brian DeVille , M.D., FACC , eletrophysiologist on the medical staff at THE HEART HOSPITAL Baylor Plano, added:
“Interventional physicians want to leverage advanced technology that minimizes surgical risks to the patient while increasing the likelihood of a favorable outcome. The new Niobe ES system will enable electrophysiologists on the medical staff to deliver therapy in a precise manner, while reducing X-ray exposure and procedure time for our patients.”
Michael P. Kaminski , President and CEO of Stereotaxis, summarized:
“The initial feedback and interest in our new Epoch platform has been very favorable. We look forward to continuing to build on the momentum of this milestone and have commitments for 12 additional system upgrades to Niobe ES which will be installed over the next few months.”
Stereotaxis Inc.
4320 Forest Park Avenue
Suite 100
St Louis, MO 63108
Tel: 314-678-6100
Fax: 314-678-6159
http://www.stereotaxis.com
Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital’s interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias.
Stereotaxis ‘ Odyssey portfolio of products provides an innovative enterprise solution for integrating, recording and networking interventional lab information within hospitals and around the world.